Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma

Dueland, Svein; Foss, Aksel; Solheim, J.; Hagness, Morten; Line, Pål–Dag

doi:10.1002/bjs.10769

Cited by 62 publications

(49 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Similar to the experience seen in liver resection [24][25][26] and palliative chemotherapy, 27 right-sided tumors were associated with an inferior outcome, with no patient surviving 5 years. 22 Similar to the experience seen in liver resection [24][25][26] and palliative chemotherapy, 27 right-sided tumors were associated with an inferior outcome, with no patient surviving 5 years.…”

Section: Discussionmentioning

confidence: 69%

“…Because recurrence alone is not predictive of short survival, DFS is not an appropriate outcome parameter with which to assess the efficacy of LT in CRLM. 22 Similar to the experience seen in liver resection [24][25][26] and palliative chemotherapy, 27 right-sided tumors were associated with an inferior outcome, with no patient surviving 5 years. Thus, caution is probably warranted in offering these patients LT ( Figure 4B).…”

Section: Discussionmentioning

confidence: 69%

“…Similarly, a scoring system based on morphology of liver lesions and factors like CEA may be used for selecting patients with CRLM for LT to obtain long OS. 13,15 The majority of the patients experienced a relapse; however, in contrast to HCC with recurrence, the CRC cohort had a long OS from the time of relapse, 22 2B, and 3B). The tradeoff in applying very stringent criteria is obviously that few patients will be eligible.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis

Dueland

Grut

Syversveen

et al. 2020

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

Patients with nonresectable colorectal cancer receiving palliative chemotherapy have a 5-year overall survival rate of about 10%. Liver transplant provided a Kaplan-Meier-estimated 5-year overall survival of up to 83%. The objective of the study was to evaluate the ability of different scoring systems to predict long-term overall survival after liver transplant. Patients with colorectal cancer with nonresectable liveronly metastases determined by computed tomography (CT)/magnetic resonance imaging/positron emission tomography (PET)-CT scans from 2 prospective studies (SECA-I and -II) were included. All included patients had previously received chemotherapy. PET-CT was performed within 90 days of the liver transplant. Overall survival, disease-free survival, and survival after relapse based on the Fong Clinical Risk Score, total PET liver uptake (metabolic tumor volume), and Oslo Score were compared. At median follow-up of 85 months for live patients, Kaplan-Meier overall survival rates at 5 years were 100%, 78%, and 67% in patients with Fong Clinical Risk Score 0 to 2, metabolic tumor volume-low group, and Oslo Score 0 to 2, respectively. Median overall survival was 101, 68, and 65 months in patients with Fong ClinicalRisk Score 0 to 2, metabolic tumor volume-low, and Oslo Score 0 to 2. These selection criteria may be used to obtain 5-year overall survival rates comparable to other indications for liver transplant. K E Y W O R D Scancer/malignancy/neoplasia, cancer/malignancy/neoplasia: metastatic disease, clinical research/practice, clinical trial, liver disease: malignant, liver transplantation/hepatology

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis

Dueland

Grut

Syversveen

et al. 2020

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…122 Moreover, a retrospective analysis using the SECA-I data was able to select a low-risk population (Oslo score 0-3) with a 5-year OS rate of 75%. 127 Another retrospective analysis on the SECA study data helped identify other predictors of post-transplant OS, such as the 'metabolic tumour volume' and 'the total lesional glycolysis' of the CLRM measured by 18 F-FDG PET/CT, 128 which could have a role in identifying patients with minor extrahepatic disease. 129 The recently published SECA-II trial showed that response to neoadjuvant chemotherapy is, in fact, important.…”

Section: Patient Selection Has To Be Refinedmentioning

confidence: 99%

Recent advances in liver transplantation for cancer: The future of transplant oncology

et al. 2019

View full text Add to dashboard Cite

Liver transplantation is widely indicated as a curative treatment for selected patients with hepatocellular carcinoma. However, with recent therapeutic advances, as well as efforts to increase the donor pool, liver transplantation has been carefully expanded to patients with other primary or secondary malignancies in the liver. Cholangiocarcinoma, colorectal and neuroendocrine liver metastases, and hepatic epithelioid haemangioendothelioma are amongst the most relevant new indications. In this review we discuss the fundamental concepts of this ambitious undertaking, as well as the newest indications for liver transplantation, with a special focus on future perspectives within the recently established concept of transplant oncology.

show abstract

“…A hard but potentially curative treatment, such as LT, should be offered to (often young) patients, taking into consideration that, so far, the only alternative is the perspective of chronic cancer. Indeed, LT is becoming a game changer in the treatment of other secondary liver malignancies15,16 and LT from living donation is a resourceful approach in transplant oncology. Livingdonor LT often constitutes the treatment of last resort in case of notyet-validated indications, which, in many allocation systems, prevent such patients from being registered on the waiting list.…”

mentioning

confidence: 99%

Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case

Iesari

Mocchegiani

Nicolini

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

The gastrointestinal stromal tumor (GIST) is a digestive neoplasm of mesenchymal lineage. The treatment strategy for receptor tyrosine kinase‐mutated GISTs is well defined. Wild‐type GISTs (WT‐GISTs) respond unsatisfactorily to specific kinase inhibitors. Moreover, evidence shows that repeat surgery has limited benefit. We report the case of a young female patient who was diagnosed with liver metastatic WT‐GIST, after initial radical resection and adjuvant therapy with molecular targeted drugs. Due to the disease progression, a two‐stage surgery was performed, with the removal of extrahepatic lesions followed by a total hepatectomy. The patient is disease‐free after 4 years from liver transplantation (LT), performed under everolimus‐based immunosuppression. The treatment of WT‐GISTs remains a significant challenge due to the frequent resistance to tyrosine kinase inhibitors (TKIs). Liver transplantation might represent an effective treatment option for such disease.

show abstract

Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma

Abstract: The low-risk group of patients with colorectal cancer and unresectable liver-only disease had a 5-year OS rate following liver transplantation similar to that of patients with HCC with lesions within the Milan criteria.

Cited by 62 publications

References 23 publications

Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis

Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis

Recent advances in liver transplantation for cancer: The future of transplant oncology

Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case

Contact Info

Product

Resources

About